arrow
K

Karen Bisnauthsing

department of research and development
H指数:30
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Erratum to “Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO): A feasibility randomised controlled trial” [J Infect 91 (2025) 106504]

勘误:“Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO): A feasibility randomised controlled trial” [J Infect 91 (2025) 106504]

2025-08-140
PREAI
Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO): A feasibility randomised controlled trial

粪菌移植以根除胃肠道中抗生素耐药菌的定植(FERARO):一项可行性随机对照试验

2025-05-160
OA
Global patterns of antigen receptor repertoire disruption across adaptive immune compartments in COVID-19
2022-08-0910
OAAI
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

RH5疫苗接种后人类血液阶段疟疾生长和免疫相关性降低

MED
IF11.8
2021-06-0185
OAAI
A dynamic COVID-19 immune signature includes associations with poor prognosis (vol 26, pg 1623, 2020)
2020-11-2713
OAAI
Translational Research in the Time of COVID-19-Dissolving Boundaries
2020-09-306
OAAI
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
2020-09-2482
OAAI
A dynamic COVID-19 immune signature includes associations with poor prognosis (vol 56, pg 512, 2020)
2020-09-092
OAAI
A dynamic COVID-19 immune signature includes associations with poor prognosis

动态新型冠状病毒肺炎免疫特征包括与不良预后的关联

2020-08-17705
OAAI
Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome
ANALYST
IF3.3
2020-01-0120
OAAI
Oral versus Intravenous Antibiotics for Bone and Joint Infection

口服与静脉注射抗生素治疗骨和关节感染

2019-01-31527
OAAI
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial

延长脉冲非达索霉素与万古霉素治疗60岁及以上患者艰难梭菌感染 (EXTEND): 一项随机、对照、开放标签的3b/4期试验

2018-03-01149
PREAI